We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website. You can decide for yourself which categories you want to deny or allow. Please note that based on your settings not all functionalities of the site are available.
Further information can be found in our privacy policy.
Recent Comments
It has been an exciting journey to see our ultra-long-acting injectable formulation make it through several years of development and learnings along the way to finally bring it to a place where we demonstrated the ability to achieve critical milestones including: 1) the ability to develop a stable and safe injectable formulation of cabotegravir (CAB); 2) sustain plasma CAB levels in macaques above the benchmark for HIV pre-exposure prophylaxis (PrEP; 4x PA-IC90) for more than 6 months; 3) demonstrate the ability to safely remove the implant and reduce CAB plasma levels by up to 100-fold within 1 week; and 4) demonstrate 100% protection in macaques over several months which represents to our knowledge the longest documented PrEP activity seen with a single CAB administration.
I am excited to continue to move forward this technology and pave the way towards clinical translation to ultimately make an impact to curb the HIV epidemic.